For Moderna, COVID vaccines were a ‘proof of concept’

The breakthrough mRNA technology that underpins the world’s first approved COVID-19 vaccines has now emerged as a critical element of the biopharmaceutical pipeline, extending from cancer to rare diseases. Amongst its peers, Moderna, a clinical leader in this field, has 48 mRNA programs in various stages of development, ranging from preclinical to phase 3, distinguishing it in a field that has been in the making for decades. The COVID vaccine’s urgency, which includes Pfizer and BioNTech’s Comirnaty, was a test of the efficacy of the mRNA technology, and Moderna is now capitalizing on these tools to usher in a new era of therapies.

Read Here.